Conditions: Esophageal Cancer Gastric Cancer
Keywords: Esophagus Gastric Adenocarcinoma EGFR matuzumab EMD 72000 randomized Epirubicin cisplatin capecitabine Metastatic Esophago-Gastric cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 72
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Participants invited to take part have metastatic cancer of the esophagus (gullet) or stomach.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Matuzumab intervention 2: Epirubicin intervention 3: Cisplatin intervention 4: Capecitabine
Intervention descriptions: intervention 1: Participants will receive matuzumab 800 milligrams (mg) intravenously (IV) every week, until disease progression (PD), unacceptable toxicity, death, or consent is withdrawn. intervention 2: Participants will receive epirubicin 50 milligrams per square meter (mg/m\^2) on Day 1 of 21-day cycle up to a maximum of 8 cycles. intervention 3: Participants will receive cisplatin 60 mg/m\^2 on Day 1 of 21-day cycle up to a maximum of 8 cycles. intervention 4: Participants will receive capecitabine 1250 mg/m\^2 daily in a 21-day cycles up to a maximum of 8 cycles.

Protocol document: